All posts by: Michael Zand

About Michael Zand

How I use biology as a tool for building – Baltimore Business Journal

Continue reading

2017-12-06 NEWS

How I use biology as a tool for building
Baltimore Business Journal
In 2010, I had some students who wanted to participate in an international competition in synthetic biology, called iGem. They asked if I’d be the faculty advisor and I said ‘Okay,’ but they had a hard time getting enough people for a team together. I

Continue reading

2017-12-06 NEWS

Stem Cell Treatment Targeting Spinal Cord Won’t Slow ALS, Researchers Say
ALS News Today
Using stem cell treatments to protect motor neurons is not enough to prevent the loss of nerve-muscle connections and disease progression in a mouse model of amyotrophic lateral sclerosis (ALS), researchers from Italy found. The study, published in the

and more »

Continue reading

2017-12-06 NEWS

Endpoints News

Looking for the next big breakthrough in CART, Mike Gilman debuts Obsidian with $49.5M round
Endpoints News
Building off some research work he’d done in the lab for years, the crew has been working with what he calls destabilizing domains, mutants which can be encoded in a “synthetic biologic cassette,” packaged in a vector and dispatched to tinker with an
Obsidian launches with $49.5 million to fine tune cellular and gene therapiesChemical & Engineering News
Biogen vet launches cancer drug startup with $50M from GV, othersBoston Business Journal
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy …Business Wire (press release)

all 5 news articles »

Continue reading

2017-12-06 NEWS

Gilman’s Next CEO Trick: Taming CART Cells With Obsidian
Xconomy
Genetically modified medicine is here. Two CAR-T therapies, made from a patient’s living T cells, are on the market in the U.S., and many more are in various stages of clinical testing. As remarkable as they might seem, however, these medicines are